SCHEMBL2403504

SCHEMBL2403504

CCCCN(CCCC)c1c2c(nc3c(-c4ccc(OC)cc4Cl)c(C)nn13)COC2

nearest known ligand 0.67

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
CRHR1 P34998 17/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL3608069 0.99 CRHR1 (0.66) CRHR1
SCHEMBL2402357 0.98 CRHR1 (0.65) CRHR1
Hydrochloric Acid SCHEMBL2406327 0.97 CRHR1 (0.64) CRHR1
SCHEMBL2403771 0.97 CRHR1 (0.65) CRHR1
SCHEMBL2403355 0.96 CRHR1 (0.67) CRHR1
SCHEMBL2402816 0.96 CRHR1 (0.62) CRHR1
Hydrochloric Acid SCHEMBL2402758 0.96 CRHR1 (0.64) CRHR1
Hydrochloric Acid SCHEMBL3615322 0.96 CRHR1 (0.66) CRHR1
Hydrochloric Acid SCHEMBL2406099 0.95 CRHR1 (0.61) CRHR1
SCHEMBL2403818 0.94 CRHR1 (0.61) CRHR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1832590-B1 Heterotricyclic compounds as CRF receptor antagonists ONO PHARMACEUTICAL CO (JP) 2011-09-28 EP claimed
US-20090137604-A1 TRI-HETEROCYCLIC COMPOUNDS AND A PHARMACEUTICAL COMPRISING THEM AS AN ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2009-05-28 US claimed
US-20060122392-A1 Tri-heterocyclic compounds and a pharmaceutical comprising them as an active ingredient ONO PHARMACEUTICAL CO., LTD. 2006-06-08 US claimed
US-20040072833-A1 Tricyclic and heterocyclic derivative compounds and drugs containing these compounds as the active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2004-04-15 US claimed
US-7807688-B2 Tri-heterocyclic compounds and a pharmaceutical comprising them as an active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2010-10-05 US disclosed
US-7807688-B2 Tri-heterocyclic compounds and a pharmaceutical comprising them as an active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2010-10-05 US disclosed
US-20090137604-A1 TRI-HETEROCYCLIC COMPOUNDS AND A PHARMACEUTICAL COMPRISING THEM AS AN ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2009-05-28 US disclosed
US-20090137604-A1 TRI-HETEROCYCLIC COMPOUNDS AND A PHARMACEUTICAL COMPRISING THEM AS AN ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2009-05-28 US disclosed
US-7459459-B2 Tri-heterocyclic compounds and a pharmaceutical comprising them as an active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2008-12-02 US disclosed
US-7459459-B2 Tri-heterocyclic compounds and a pharmaceutical comprising them as an active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2008-12-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060122392-A1 Tri-heterocyclic compounds and a pharmaceutical comprising them as an active ingredient NR3C1, CRHR2, CRHR1 CRHR1 3/4885
US-20090137604-A1 TRI-HETEROCYCLIC COMPOUNDS AND A PHARMACEUTICAL COMPRISING THEM AS AN ACTIVE INGREDIENT NR3C1, CRHR2, CRHR1 CRHR1 3/4885
US-20040072833-A1 Tricyclic and heterocyclic derivative compounds and drugs containing these compounds as the active ingredient CRH, CRHR1, CRHR2 CRHR1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.